1. ASCL1 phosphorylation and ID2 upregulation are roadblocks to glioblastoma stem cell differentiation
- Author
-
Roberta Azzarelli, Aoibheann McNally, Claudia Dell’Amico, Marco Onorati, Benjamin Simons, Anna Philpott, Apollo - University of Cambridge Repository, Simons, Benjamin [0000-0002-3875-7071], and Philpott, Anna [0000-0003-3789-2463]
- Subjects
631/67 ,Multidisciplinary ,Brain Neoplasms ,Science ,Amino Acid Motifs ,Cell Cycle ,article ,Cell Differentiation ,CAmbridgeStemCellInstitute ,Gene Expression Regulation, Neoplastic ,Basic Helix-Loop-Helix Transcription Factors ,Neoplastic Stem Cells ,Humans ,Medicine ,Phosphorylation ,631/80 ,631/136 ,631/532 ,Glioblastoma ,Inhibitor of Differentiation Protein 2 - Abstract
The growth of glioblastoma (GBM), one of the deadliest adult cancers, is fuelled by a subpopulation of stem/progenitor cells, which are thought to be the source of resistance and relapse after treatment. Re-engagement of a latent capacity of these cells to re-enter a trajectory resulting in cell differentiation is a potential new therapeutic approach for this devastating disease. ASCL1, a proneural transcription factor, plays a key role in normal brain development and is also expressed in a subset of GBM cells, but fails to engage a full differentiation programme in this context. Here, we investigated the barriers to ASCL1-driven differentiation in GBM stem cells. We see that ASCL1 is highly phosphorylated in GBM stem cells where its expression is compatible with cell proliferation. However, overexpression of a form of ASCL1 that cannot be phosphorylated on Serine–Proline sites drives GBM cells down a neuronal lineage and out of cell cycle more efficiently than its wild-type counterpart, an effect further enhanced by deletion of the inhibitor of differentiation ID2, indicating mechanisms to reverse the block to GBM cell differentiation.
- Published
- 2022